Dementia with lewy bodies patients with high tau levels display unique proteome profiles
This molecular-level data supports the idea of neurodegenerative disease as a continuum of diseases with distinct PTM profiles DLBTau<sup>+</sup> and DLBTau<sup>-</sup> patients in comparison to AD. These findings further emphasize the importance of identifying specific and tailored therapeutic approaches targeting the involved proteopathies in the neurodegenerative disease spectrum.
Authors
- Hanno Steen (ORCID: https://orcid.org/0000-0003-0179-6648)
- Sabina Berretta (ORCID: https://orcid.org/0000-0002-4057-7766)
- Christoph N. Schlaffner (ORCID: https://orcid.org/0000-0003-2717-3406)
- Judith A. Steen (ORCID: https://orcid.org/0000-0002-8167-0772)
- Elisabeth S. Lawton
- Hanne van der Heijden (ORCID: https://orcid.org/0009-0007-2636-221X)
- Deeptarup Biswas (ORCID: https://orcid.org/0000-0002-5422-0303)
- Mukesh Kumar (ORCID: https://orcid.org/0000-0001-8266-633X)
- Sinead Greally
Institutions
- Boston Children's Hospital (US)
- Harvard University (US)
- Hasso Plattner Institute (DE)
- University of Potsdam (DE)
- McLean Hospital (US)
Publication Details
- Journal
- Molecular Neurodegeneration
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1186/s13024-024-00782-0
- Citations
- 4
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- Michael J. Fox Foundation for Parkinson's Research
- McLean Hospital
- National Institutes of Health
- Tau Consortium
- National Institute on Aging